Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...

Please provide your email address to receive an email when new articles are posted on . The tucatinib combination resulted in a 36% reduction in risk for disease progression or death. Median PFS was ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

To achieve approval for use in clinical practice, new drugs in development must demonstrate exceptional anti-tumor activity together with acceptable tolerability and demonstrate superiority over the ...

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). 6mg/kg and above ORR(%) ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, Jazz Pharmaceuticals is seeing its vision with Ziihera come into clearer ...

The Company plans to submit an sBLA for the GEA indication in the first half of 2026. Topline data were announced from a phase 3 study evaluating zanidatamab-hrii for the first-line treatment of human ...